Research Article

Uptake of $^{18}$F-FET and $^{18}$F-FCH in Human Glioblastoma T98G Cell Line after Irradiation with Photons or Carbon Ions

Francesca Pasi,1,2 Marco Giovanni Persico,3,4 Federica Eleonora Buroni,3 Carlo Aprile,3,5 Marina Hodolic,6 Franco Corbella,1 Rosanna Nano,2 Angelica Facoetti,5 and Lorenzo Lodola3

1Department of Oncohaematology, Radiotherapy Unit, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
2Department of Biology and Biotechnology Lazza r o Spallanzani, University of Pavia, Via Ferrata 9, 27100 Pavia, Italy
3Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
4Scuola Universitaria Superiore IUSS Pavia, Pavia, Italy
5National Centre for Oncological Hadrontherapy (CNAO), Via Campeggi 53, 27100 Pavia, Italy
6Nuclear Medicine Research Department, JASON GmbH, Graz, Austria

Correspondence should be addressed to Carlo Aprile; c.aprile@smatteo.pv.it

Received 29 July 2016; Revised 10 November 2016; Accepted 26 December 2016; Published 15 January 2017

Academic Editor: Ralf Schirrmacher

Copyright © 2017 Francesca Pasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The differential diagnosis between recurrence of gliomas or brain metastases and the phenomenon of radiation necrosis plays an important role in both therapeutic and prognostic settings. The distinction between tumor recurrence and radionecrosis is important in order to choose the best subsequent therapy and prognosis is guided by the cause of progression. Necrosis is an important histological feature of glial tumors. Tumor necrosis is ischemic in nature, due to an insufficient blood supply [1]. The differential diagnosis is complicated by the fact that late radionecrosis appears at various times after treatment, from 6 months up to several years [2]. Moreover, radionecrosis phenomenon is observable without the direct involvement of the brain in the field of radiation (bystander effect, e.g., head and neck cancer irradiated with hadrons). Nowadays, despite the enormous improvement of diagnostic modalities, including the various applications of MRI, CT, and PET, the diagnosis and grading of primary brain tumours lack sufficient accuracy. This is more relevant when recurrence after therapy, early neuroinflammation [3], or late radionecrosis is concerned [4]. Despite the technological advances and new MR investigable parameters [5], there is a wide area that does not allow the reasonable accuracy that the clinicians need. Also, PET radiopharmaceuticals ($^{11}$C-METH, $^{18}$F-FET, $^{18}$F-FCH, and $^{18}$F-DOPA) have limitations mainly in terms of specificity, although the dynamic investigation, only possible with

1. Introduction

The differential diagnosis between recurrence of gliomas and brain metastases and the phenomenon of radiation necrosis plays an important role in both therapeutic and prognostic settings. The distinction between tumor recurrence and radionecrosis is important in order to choose the best subsequent therapy and prognosis is guided by the cause of progression. Necrosis is an important histological feature of glial tumors. Tumor necrosis is ischemic in nature, due to an insufficient blood supply [1]. The differential diagnosis is complicated by the fact that late radionecrosis appears at various times after treatment, from 6 months up to several years [2]. Moreover, radionecrosis phenomenon is observable
2. Materials and Methods

2.1. Cell Culture. Human glioblastoma T98G cells were obtained from the European Collection of Cell Cultures (Porton Down, Salisbury, UK). T98G cells were cultured in Eagle’s minimum essential medium (EMEM; Euroclone SpA, MI, Italy) supplemented with 10% foetal bovine serum in Eagle’s minimum essential medium (EMEM; Euroclone SpA, MI, Italy). T98G cells were cultured obtained from the European Collection of Cell Cultures.

2.2. Irradiation Treatments. Cells were irradiated at doses of 2 Gy, 10 Gy, and 20 Gy with photons at room temperature using a LINAC at 6 MeV (ELEKTA Synergy; Radiotherapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) with a dose rate of 3 Gy/min. The flasks containing the cells were placed vertically at the isocenter and a 5 mm thick plastic sheet was placed below the flask surface to allow dose buildup (Figure 2(b)). Cells irradiation with carbon ions (energy range: 246–312 MeV/u) was performed using the synchrotron clinical beam at the National Centre for Oncological Hadrontherapy (CNAO) in Pavia, Italy [11]. The flasks were placed vertically in a water phantom on the patient’s couch, so that the surface at which the cells were stuck was at 15 cm depth, corresponding to the mid Spread-Out Bragg Peak (SOBP), where the SOBP was obtained with active beam modulation. Carbon ions Linear Energy Transfer (LET) in the mid SOBP, evaluated with a Monte Carlo Fluka simulation, was 40 keV/μm. The irradiation dose was 2 Gy (physical dose) for each sample (dose rate of 0.7 Gy/min) (Figure 2(a)) [12].

2.3. Radioactive Tracer Incubation. 18F-FCH and 18F-FET were obtained from IASON GmbH (Graz-Seiersberg, Austria). Cells, seeded at a density to obtain 2 × 10^5 cells per flask when irradiation treatments were performed, grew adherent to the plastic surface at 37°C in 5% CO2 in complete medium. Irradiation treatment was performed 20 h after the cell seeding. Radioactive tracer experiments were performed 36 hours after irradiation. The medium was renewed before performing the studies. Cells were incubated at 37°C with 100 kBq (100 μCi) equimolar amounts of 18F-FCH or 18F-FET, added to 2 mL of medium in each flask for varying incubation times (20, 40, 60, 90, and 120 min or 20, 40, 60, 80, 100, and 120 min according to availability of cells) under 5% CO2 gaseous conditions. Radiotracer incubation was done in complete medium. Control samples underwent the same procedure as other samples, but they were incubated with 100 μL of saline instead of a radiotracer.

2.4. Cell Kinetic Studies and Uptake Evaluation. The cellular radiotracer uptake was determined with a 3 × 3″ NaI (TI) pinhole 16 × 40 mm gamma counter (Raytest, Straubenhardt, Germany). All measurements were carried out under the same counting position along with a standardized source to verify the counter’s performance and the data were corrected for background and decay. Total radioactivity was counted when the radiotracer was added to the medium in each flask (time 0). After 20, 40, 60, 90, and 120 min or 20, 40, 60, 80, 100, and 120 min from time 0, the medium was harvested, the cells were rapidly washed three times with 1 mL of phosphate-buffered saline (PBS), and radiopharmaceutical uptake for each sample was assessed. The uptake measurements are expressed as the percentage of the administered dose of tracer per 2 × 10^5 cells after correction for negative control uptake (flasks containing no cells with complete medium and incubated with a radiopharmaceutical).

2.5. Cell Viability Assay. At the end of quantitative gamma spectrometry, adherent cells were harvested with 1% trypsin-EDTA solution and supernatants with adherent cells were
counted with Burker's chamber. Trypan Blue dye assay was performed to assess cell viability as standard protocol. Finally, we calculated the % of cell viability: number of cells adherent to the flask after irradiation versus the nonirradiated samples.

2.6. Cell Death Analysis and Morphology Evaluation. To evaluate the cell death and morphology changes induced by radiation treatment, May–Grunwald–Giemsa staining [13] and Annexin V-propidium iodide (Ann-PI) [14] assays were performed on irradiated T98G cells. \(2 \cdot 10^4\) cells were seeded on coverslip slides 24 hours before treatments. Cells were irradiated at 2, 10, and 20 Gy and after 36 hours from treatment the slides were stained. A group of T98G cells were sham-irradiated and handled in parallel with irradiated cells. T98G cells were stained with May–Grunwald–Giemsa stain (Sigma-Aldrich, St. Louis, MO, USA) according to standard protocol and examined under 400x power using a light microscope (Leica DM LB2; Wetzlar, Hesse, Germany). This qualitative analysis evaluates the morphology, the shape, and the density of cells. The Ann-PI test, carried out according to the manufacturer's instructions (eBioscience, San Diego, CA, USA), is based on fluorescence technique that allows distinguishing viable, damaged, or dead cells. In radiobiology, they can be used to identify cell damage induced by radiation. The membrane status can be monitored using some specific probes like Annexin V and PI. Permeability depends on the physicochemical characteristics of the fluorochrome molecule and on the function of the cell membrane that can indicate the viability of cells. This analytical approach discriminates live cells from damaged ones, through correlated analysis of the two fluorescent signals acquired with parallel observations with phase contrast microscopy. In particular, the dual staining with Annexin V and PI permits identifying the different levels of damage in a cell population that could include viable cells with intact membrane (no or little fluorescence), early damaged cells with partial disruption of membrane (green fluorescence), and late damaged cells with a loss of membrane integrity that could lead to cell death (both red and green fluorescence). These populations were distinguished easily on an Olympus BX51 microscope with standard fluorescence equipment.

The evaluation of the mean number of the Annexin/PI double labelled cells was obtained by counting cells of about ten microscopic fields. We reported the percentages of damaged cells in each irradiated and nonirradiated (control) sample.

With this approach, samples of cells can be analyzed in a short time with minimal cell manipulation, avoiding the use of trypsin that could produce additional damage and could affect the results. Moreover, May–Grunwald–Giemsa staining was used on the same samples as a rapid and routinary method to evaluate cell morphology and the presence of damaged cells.

In vitro experiments were conducted in duplicate and repeated twice. All values are expressed as mean values with confidence interval (CI 95%). The uptake of radiotracer is represented as a function of the incubation period; all values are shown in figures as a percentage of the administered dose per \(2 \cdot 10^5\) cells (mean ± CI 95%). Therefore, if error bars on the \(y\)-axis do not overlap, the two points are considered significantly different.

3. Results

3.1. Radiopharmaceuticals Binding Assay. Figure 3 shows the comparison between FCH uptake and FET uptake by T98G cells after photons irradiation (2-10-20 Gy); 0 Gy curves (controls) are reported as red dotted lines. FCH uptake increased linearly with the incubation time, and the absolute values of radiotracer uptake (%/\(2 \cdot 10^5\) cells) were enhanced with the raising of the radiation dose. The same trend was found in the kinetic curves regarding FET uptake, but the shape of the curves remained unchanged in irradiated compared to nonirradiated samples reported in Figure 3. The uptake of FET is lower than of FCH, especially after 60 min since the radiopharmaceutical incubation.
Figure 3: Uptake of FCH and FET by T98G cells after irradiation with photons at different doses compared to controls (0 Gy).

Figure 4 shows the comparison of the kinetic curves of FCH and FET uptake in T98G cells. Red lines represent the uptake relative to nonirradiated samples. The light blue lines represent the uptake of irradiated (2 Gy of carbon ions) samples.

For the “0 Gy” curves (red dotted lines), the highest uptake of FCH was observable at 90 and 120 min. The percentage uptake of FET in comparison to FCH was lower by a factor of more than 3, but the two kinetic curves were different. In fact, while FCH curves showed a progressive rise reaching a maximum after 120 min, FET showed more rapid initial uptake up to 40 min.

After the irradiation with carbon ions, T98G cells constantly increased the uptake of FCH along the incubation time with a final peak after 120 min, while the kinetic curve relative to FET uptake was quite similar to the nonirradiated samples curve, even if the radiotracer uptake (%/2·10⁵ cells) was a bit higher at 60 and 100 min incubation time.

Figure 5 illustrates the comparison of FCH uptake in T98G cells after photons or carbon ions irradiation. Irradiation of the cells with 2 Gy carbon ions seemed to lead to a similar result of 2 Gy photons treatment, except for 120 min incubation time where the maximum uptake of FCH by T98G was reached with carbon ions.

Figure 6 shows the uptake of FET by T98G cells after irradiation with photons or carbon ions (2-10-20 Gy or 2 Gy, resp.). The curves showed less evident uptake of FET after 2 and 10 Gy delivered by photons than after 2 Gy delivered by carbon ions. The kinetics curves were also different, with a peak at 100 min in the 2 Gy carbon ions irradiated samples instead of the 40 min peak observable in the photons irradiated ones.

As a negative control, flasks containing medium without cells, incubated under similar conditions, showed a non-significant presence of radiotracers.

3.2. Cell Viability. The values of cell viability (cells adherent to the flasks versus nonirradiated samples) after irradiation with
and carbon ions (2Gy). Moreover, in irradiated cells, the presence of damaged cells was observed. The number of giant cells as a consequence of cell death was 21% after 20 Gy treatment, 9% after 10 Gy, and 6% (20 Gy), while after irradiation with 2 Gy of carbon ions, the value was 65% ± 12% (Figure 7).

An increased number of fluorescent cells were noticed in cells treated with 20 Gy photon radiation, suggesting that dose induced more consistent damage: an increase in the amount of green and red fluorescent cells, respectively, in the presence of different cell morphologies. Annexin V and PI positive, was observed compared with control (Figures 9(a), 9(b), and 9(c)). Taking account of the values of cell viability after irradiation, the percentage of damaged cells was 21% after 20 Gy treatment, 9% after 10 Gy, and 4% after 2 Gy compared with the 3% of the 0 Gy control cells (CI536 ± 3%).

May–Grunwald–Giemsa stain (Figure 10(a)) shows that control cells were polynucleated in active proliferation with cell heterogeneity, in the presence of different cell morphologies, which are typical characteristics of T98G cells. Irradiated samples show a decrease of cell number with the increase of dose radiation, suggesting that radiation causes detachment of dead cells from the surface (Figures 10(b), 10(c), and 10(d)).

Moreover, in irradiated cells, the presence of damaged cells with karyorrhexis and karyolysis was observed as well as an increase in the number of giant cells as a consequence of damage induced by radiation treatments (Figures 10(b), 10(c), and 10(d)). They appeared to increase dependently on dose radiation and seemed to be not reversible and repairable at 20 Gy (Figure 10(d)).

### 4. Discussion

The aim of our research project is to investigate in vitro the different radiopharmaceuticals uptake by T98G glioblastoma cells, involved in the development of radiation necrosis, after different irradiation conditions with photons or carbon ions.

The in vitro model used in our experiments allows the direct comparison of different radiopharmaceuticals as potential candidates for neurooncological PET imaging. In our previous study [15], we compared the uptake of FCH and FDG by T98G glioblastoma cells and fibroblasts. The results showed superiority of FCH in terms of absolute uptake and an optimal target to nontarget ratio in the brain, whereas the major limitation of FDG is its physiological parenchymal uptake. The study proved the efficacy of FCH, better than FDG in establishing the tumor-to-background ratio in brain tumors. However, direct translation to clinical application is hampered by certain conflicting results reported in the literature [9, 16].

Subsequently, we tested the FET affinity for neoplastic tissue, confirming its potential as a viable oncological PET marker [17].

FET could be more useful in the presence of reparative changes after therapy, where the higher affinity of FCH to inflammatory cells makes it more difficult to distinguish between tumor persistence and nonneoplastic, radiochemotherapy related changes [18].

In this work, we evaluated the uptake of FCH and FET with different metabolic aspects, in basal conditions and after irradiation with photons (conventional LINAC) or hadrons (carbon ions).

The goal of our experiment was to evaluate the uptake of two radiotracers used in the diagnosis and follow-up of glioblastoma after radiotherapy, in other words to evaluate in which way the radiation delivered to tumor cells can modify the uptake and metabolism of FCH and FET. This aspect has a deep impact on PET imaging, where early and late radionecrosis phenomena can constitute a diagnostic dilemma [19], frequently unresolved by the other diagnostic modalities as MRI and CT.

The radiation dose we used, either of photons or of carbon ions, largely exceeded the limit of increased sensitivity to acute dose described as low-dose hyperradiosensitivity (HRS) and is in the range of increased radioreistance (IRR) where the radiation damage leads to the activation of a repair process and follows a linear model [20]. In fact, data relative to the number of cells adherent to the flask 36 hours after irradiation and 2 hours after incubation with the radiopharmaceutical fit exactly ($R^2 = 0.996$) with an exponential equation ($77.06e^{-0.035D}$) (Figure 7).

The FCH uptake after photons irradiation (Figure 4) tends to increase as dose increases, and the uptake pattern is more linear with time, still increasing at the end of observation (2 hours) without the transient washout at 60 minutes we previously described [15, 17] in nonirradiated cells. Such uptake pattern is about the same if we consider...
the 2 Gy curve of both photons and carbon ions (Figures 5 and 6); however, the uptake at the end of observation is about 1% higher with carbon ions.

The FET uptake after photons (Figure 5) irradiation shows a marked decrease at 2 Gy, while after 10 Gy irradiation it is about the same for nonirradiated cells and increases markedly after 20 Gy irradiation. The effect after 2 Gy irradiation of carbon ions is less evident, characterized by small, albeit significant uptake increasing without change of the time activity curve.

A direct comparison of the effect of the two different radiation sources is hampered by the fact that only 2 Gy data are available for carbon ions. However, the more pronounced effect of carbon ions could be related to higher LET [20].

Despite the fact that the number of viable cells, adherent to the surface of the flask, decreases with the increasing of radiation dose, along with major evidence of altered membrane permeability and morphological changes, the uptake of both tracers we studied tends to increase. From these results, it appears that the cells, which survived from the treatment, seem to take more radiopharmaceuticals for high doses of radiation compared to low doses and control. This phenomenon can be due to the fact that these radioresistant cells are highly reactive and able to capture more of FCH for the membrane metabolism.

Methods based on cell membrane permeability using fluorescent probes are the most established and are routinely used in many applications [14]. As our results suggest, radiation injury could induce increased permeability of membrane. Cells may respond to radiation injury with increased activities which may be regarded as stimulation secondary to a preceding injury. Some of the responses of this kind are involved in the processes of recovery from injury and can result in visible changes in cells [21, 22].

It is possible to postulate that viable (adherent) cells enhance their mechanisms of repair and resistance. Millet and coworkers [23] showed in the same cell line that radiation upregulates telomerase activity, demonstrating a PIK3/AKT-independent pathway of telomerase activation. In the literature, radiation seems to be responsible for the upregulation of choline kinase and/or choline transporter [24, 25] as well as of L-amino acid transporter LAT1 [26].

It is interesting to note that even if the absolute uptake per flask is taken into account (data not shown) without normalization to $2 \times 10^5$ cells, the same uptake pattern is recognizable, characterized by increased uptake of both radiopharmaceuticals, further confirming the upregulation mechanism.

These upregulation mechanisms can affect the interpretation of PET images obtained with both radiopharmaceuticals in the assessment of response to radiotherapy, indicating either a tumor burden larger than the one actually present or, more likely, the persistence of a subpopulation of cancer cells.
with acquired radioresistance when a dosage is in the range of increased radioresistance (IRR).

Our data suggest that FCH and FET could be useful to analyze different metabolic pathways of glioblastoma cells before and after radiotherapy in accordance with Galldiks et al. [27]. The paradox effect on FET uptake after irradiation has been previously described in MCF7 cell line [28]. Many factors could be involved including p53mt expression and selection of more aggressive radioresistant clones.

Further studies shall be conducted to study the uptake of radiopharmaceuticals by irradiated cells after a longer time between irradiation and analysis to assess over time the phenomenon of radiation-induced damage repair.

5. Conclusions

The differential diagnosis between tumor recurrence and early and late radionecrosis constitutes a real dilemma for physicians. Both FET and FCH are able to trace tumor behavior in terms of higher uptake for increased doses of radiation treatment, attributable to the upregulation of cells attempts to repair nonlethal damage. This phenomenon appeared to be more evident for FCH due to the role of choline in increased membrane metabolism. Our data suggest that both FCH and FET could be useful to analyze the metabolic pathways of glioblastoma cells before and after radiotherapy, providing information on their greater or lower metabolic status.

In order to indirectly translate our results into clinical application, physicians will have to consider the different kinetics pathways of uptake concerning the two radiopharmaceuticals. The future step will be to test the behavior of other cell types such as neoplastic, endothelial, and microglia cells incubated with medium harvested from these irradiated cells, containing inflammatory and growth factors, cytokines, receptor ligands, and other factors that could contribute to the development of radiation necrosis. The new experiments will let us study the effect of these inflammation media on distant radionecrosis-neuroinflammation development.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Authors’ Contributions

Francesca Pasi, Marco Giovanni Persico, and Federica Eleonora Buroni contributed equally.

Acknowledgments

The authors wish to thank Professor Mazzini Giuliano (Molecular Genetics Institute, National Research Council and Biology and Biotechnology Department “L. Spallanzani”) for his expertise in cell microscopy and cytometry.
References

[1] O. Şen, M. V. Aydin, N. Altinörs, B. Erdoğan, F. Kayaseçuk, and O. Kızılkılıç, "Recurrence tumor or radionecrosis," Turkish Neurosurgery, vol. 14, no. 1-2, pp. 41–44, 2004.

[2] F. Bayramli, A. Dinçer, A. Sav, E. Vardareli, and S. Peker, "Late brain stem radionecrosis seventeen years after fractionated radiotherapy," Turkish Neurosurgery, vol. 19, no. 2, pp. 182–185, 2009.

[3] M. Herrera-Rivero, M. T. Heneka, and V. Papadopoulos, "Translocator protein and new targets for neuroinflammation," Clinical and Translational Imaging, vol. 3, no. 6, pp. 391–402, 2015.

[4] Y. Yoshii, "Pathological review of late cerebral radionecrosis," Brain Tumor Pathology, vol. 25, no. 2, pp. 51–58, 2008.

[5] S. Betke, P. Peschke, J. Kaesmacher et al., “Static FET–PET and MR Imaging in Anaplastic Gliomas (WHO III),” World Neurosurgery, vol. 91, pp. 524–531.e1, 2016.

[6] S. Betke, J. Gempt, C. Delbridge et al., "Prognostic value of O-(2-[18F]-Fluorooethyl)-L-Tyrosine positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma," World Neurosurgery, vol. 89, pp. 230–239, 2016.

[7] N. Testart-Dardel, M. Gómez-Río, E. Triviño-Ibáñez, and J. M. Llamas-Elvira, “Clinical applications of PET using C-11/F- 18-choline in brain tumours: a systematic review,” Clinical and Translational Imaging, pp. 1–19, 2016.

[8] A. van Waarde and P. H. Elsinga, “Proliferation markers for the differential diagnosis of tumor and inflammation,” Current Pharmaceutical Design, vol. 14, no. 31, pp. 3326–3339, 2008.

[9] J. Bolcaen, B. Descamps, K. Deblaere et al., “18F-fluoromethylcholine (FCho), 18F-fluorothyrotyrosine (FET), and 18F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study,” Nuclear Medicine and Biology, vol. 42, no. 1, pp. 38–45, 2015.

[10] B. Stöber, U. Tanase, M. Herz, C. Seidl, M. Schaiger, and R. Senekwitsch-Schmidtk, “Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluorothyrotyrosine (FET) uptake in human tumour and inflammatory cells,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 8, pp. 932–939, 2006.

[11] S. Rossi, "The National Centre for Oncological Hadrontherapy (CNAO): status and perspectives," Physica Medica, vol. 31, no. 4, pp. 333–351, 2015.

[12] A. Faccoetti, B. Vischioni, M. Ciocca et al., "In Vivo radiobiological assessment of the new clinical carbon ion beams at CNAO," Radiation Protection Dosimetry, vol. 166, no. 1-4, Article ID ncv145, pp. 379–382, 2015.

[13] G. Clark, Staining Procedures, Williams & Wilkins, Baltimore, Md, USA, 3rd edition, 1973.

[14] G. Mazzini, C. Ferrari, and E. Erba, “Dual excitation multi-fluorescence flow cytometry for detailed analyses of viability and apoptotic cell transition,” European Journal of Histochemistry, vol. 47, no. 4, pp. 289–298, 2003.

[15] F. E. Buroni, F. Pasi, M. G. Persico, L. Lodola, C. Aprile, and R. Nano, "Evidence of 18F-FCH uptake in human T98G glioblastoma cells," Anticancer Research, vol. 35, no. 12, pp. 6439–6444, 2015.

[16] F. F. Calabria, M. Barbarisi, V. Gargemi, G. Grilea, and G. L. Cascini, "Molecular imaging of brain tumors with radiolabeled choline PET," Neurosurgical Review, pp. 1–10, 2016.

[17] M. G. Persico, F. E. Buroni, F. Pasi et al., "18F-FET and 18F-FCh uptake in human glioblastoma T98G cell lines," Radiation and Oncology, vol. 50, no. 2, pp. 153–158, 2016.

[18] N. Spaeth, M. T. Wyss, B. Weber et al., "Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence," Journal of Nuclear Medicine, vol. 45, no. 11, pp. 1931–1938, 2004.

[19] M. D. Piroth, M. Pinkawa, R. Holy et al., "Prognostic value of early [18F] Fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme," International Journal of Radiation Oncology Biology Physics, vol. 80, no. 1, pp. 176–184, 2011.

[20] R. Cherubini, V. de Nadal, and S. Gerardi, "Hyper-radiosensitivity and induced radiosensitivity and bystander effects in rodent and human cells as a function of radiation quality," Radiation Protection Dosimetry, vol. 166, no. 1-4, Article ID ncv294, pp. 137–141, 2015.

[21] A. Besse, J. Sana, R. Lakomy et al., "MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response," Tumor Biology, vol. 37, no. 6, pp. 7719–7727, 2016.

[22] M. Furuse, N. Nonoguchi, S. Kawabata, S.-I. Miyatake, and T. Kuroiwa, “Delayed brain radiation necrosis: pathological review and new molecular targets for treatment," Medical Molecular Morphology, vol. 48, no. 4, pp. 183–190, 2015.

[23] P. Millet, C. Granotier, O. Etienne, and F. D. Boussin, "Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines," International Journal of Oncology, vol. 43, no. 2, pp. 375–382, 2013.

[24] A. Bansal, W. Shuyan, T. Hara, R. A. Harris, and T. R. DeGrado, "Biodisposition and metabolism of [18F]fluorocholine in 9L glioma cells and 9L glioma-bearing Fisher rats," European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 6, pp. 1192–1203, 2008.

[25] C. Taguchi, M. Inazu, I. Saiki et al., “Functional analysis of [methyl-3H]choline uptake in glioblastoma cells; influence of anti-cancer and central nervous system drugs," Biochemical Pharmacology, vol. 88, no. 3, pp. 303–312, 2014.

[26] A. Habermeir, J. Graf, B. F. Sandhöfer, J.-P. Boissel, F. Roesch, and E. I. Closs, "System I amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET)," Amino Acids, vol. 47, no. 2, pp. 335–344, 2015.

[27] N. Galdiks, G. Stoffels, C. P. Filis et al., "Role of O-(2-[18F]-Fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis," Journal of Nuclear Medicine, vol. 53, no. 9, pp. 1367–1374, 2012.

[28] G. Jeong Cheon, H.-K. Chung, J.-A. Choi et al., "Cellular metabolic responses of PET radioisotopes to 188Re radiation in an MCF7 cell line containing dominant-negative mutant p53," Nuclear Medicine and Biology, vol. 34, no. 4, pp. 425–432, 2007.